Eddingpharm adds another licensed in candidate to oncology pipeline
This article was originally published in Scrip
Executive Summary
Chinese pharma enterprises are continuing to gain access to novel product candidates through licensing deals with foreign partners, Hong Kong-based Eddingpharm becoming the latest to strike a deal with a Western firm just a month after its previous tie-up.